Page last updated: 2024-12-05

triphenyl bismuth

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triphenyl bismuth (Ph3Bi) is an organobismuth compound that exists as a white solid. It is a moderately stable compound but can be oxidized in air. Synthesis typically involves the reaction of bismuth chloride with phenyl Grignard reagent. Research on triphenyl bismuth focuses on its potential applications as a precursor to other bismuth-containing compounds and its use in organic synthesis. It is also investigated for its potential as a catalyst or reagent in various chemical transformations. Its unique electronic and structural properties make it an interesting subject for studying the chemistry of bismuth.'

triphenyl bismuth: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11774
MeSH IDM0206127

Synonyms (47)

Synonym
AC-4365
c18h15bi
AKOS015840405
ai3-51412
einecs 210-033-4
epa pesticide chemical code 082801
brn 3905930
nsc 465
triphenyl bismuth
trifenylbismutin [czech]
caswell no. 896
triphenylbismuthane
nsc-465
bismuth, triphenyl-
triphenylbismuthine
nsc465
bismuthine, triphenyl-
wln: r-bi-r&r
triphenylbismuth ,
603-33-8
aerotex
bismuth triphenyl
A832697
dtxsid6042498 ,
NCGC00255966-01
cas-603-33-8
dtxcid4022498
tox21_302240
T0511
r18732f41w ,
4-16-00-01226 (beilstein handbook reference)
trifenylbismutin
unii-r18732f41w
triphenylbismuth [mi]
triphenyl bismuthane
triphenyl bismuthine
triphenylbismuthin
(c6h5)3bi
mfcd00014064
J-525123
triphenylbismuth, 98% (99.9% trace metals basis)
Q4463253
BCP13881
AMY902
SY017812
CS-0084105
triphenyl bismuth 97.5%

Research Excerpts

Overview

Triphenyl bismuth (Ph3Bi) is a promising new additive for making biomedical resins visible on x-ray images.

ExcerptReferenceRelevance
"Triphenyl bismuth (Ph3Bi) is a promising new additive for making biomedical resins visible on x-ray images. "( Cytotoxicity evaluation of a new radiopaque resin additive--triphenyl bismuth.
Bhagat, HR; Cabasso, I; Cardenas, HL; Marshall, MV; Rawls, HR, 1992
)
1.97

Toxicity

ExcerptReferenceRelevance
" Changes in cell growth, cell viability, and the visual appearance of cells were used for the assessment of toxic response."( Cytotoxicity evaluation of a new radiopaque resin additive--triphenyl bismuth.
Bhagat, HR; Cabasso, I; Cardenas, HL; Marshall, MV; Rawls, HR, 1992
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency30.06110.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency12.29980.173734.304761.8120AID1346924
SMAD family member 3Homo sapiens (human)Potency12.29980.173734.304761.8120AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency10.99760.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency35.39540.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency21.68990.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency44.00460.001022.650876.6163AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency19.16690.000417.946075.1148AID1346784; AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency19.49380.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency49.71540.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency6.96250.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency41.83860.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency54.94100.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency15.35530.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.52130.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.96620.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency19.91770.023723.228263.5986AID743223; AID743241
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.51350.001628.015177.1139AID1224843; AID1224895
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency21.87240.057821.109761.2679AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency113.00400.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency55.54850.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency50.41690.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency40.85620.000627.21521,122.0200AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency34.37620.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency34.37620.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's3 (21.43)18.2507
2000's5 (35.71)29.6817
2010's4 (28.57)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.31 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]